Evidence map›Paper›PMID 36268238›Full record

ArticleHepatobiliary surgery and nutrition2022

Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future.

Devanand Sarkar

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Devanand SarkarDepartment of Human and Molecular Genetics, Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM), Virginia Commonwealth University, Richmond, VA, USA.

Funding

The role of AEG-1 in NASH and NASH-HCCR01DK107451 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND · 2016 to 2025
$3.9M
Novel Targeted Combinatorial Therapy for Hepatocellular CarcinomaR01CA244993 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B, SARKAR, DEVANAND · 2020 to 2024
$2.7M
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinomaR01CA240004 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND, WANG, XIANG-YANG SHAWN · 2019 to 2023
$2.4M
Targeting oncogenes for hepatocellular carcinomaR01CA230561 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA230561NCI NIH HHS R01 CA240004NCI NIH HHS R01 CA244993NIDDK NIH HHS R01 DK107451
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36268238
PMCPMC9577984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.